TED Ted Baker Plc

Tepnel Life Sciences PLC
06 August 2007



PRESS RELEASE



  Tepnel Life Sciences plc receives grants to develop novel diagnostics and to
              help promote its pharmaceutical services in Scotland


Manchester, UK, 6 August 2007 Tepnel Life Sciences PLC (AIM: TED), the
international Molecular Diagnostics and Research Products & Services group,
announces that it has been awarded two grants which will be used to expand its
pipeline of human diagnostic tests and to promote future growth of its
pharmaceutical services business in Scotland.

A grant of #50,000 has been awarded by the Biotechnology and Biological Sciences
Research Council (BBSRC) to support the development of novel epigenetic
diagnostics.  The award was made under the Industry Interchange Programme which
seeks to promote the transfer of expertise between academic and commercial
organisations.

This grant relates to a research project led by Professor Mike Wilkinson, Head
of the Institute of Biological Sciences at The University of Wales Aberystwyth.
Professor Wilkinson, in collaboration with Tepnel, is developing a novel
approach to diagnostics which may be used to accurately identify a broad range
of disease states including so-called complex, psychiatric diseases.
Epigenetics (the study of reversible hereditary information not mediated by the
DNA sequence itself) is a rapidly growing field and is central to this
collaboration.

The development of novel epigenetic technology will benefit Tepnel's molecular
diagnostic and pharmaceutical service businesses by providing new and more
efficient methods to screen for epigenetic changes that indicate both
predisposition to and the development of disease. The introduction of epigenetic
based services will also complement genotyping and other molecular services at
Tepnel's new facility in Livingston allowing researchers to investigate both
epigenetic and genetic factors in disease and therapeutic development.

A business support award from Scottish Enterprise, Edinburgh and Lothians (SEEL)
will be used to support an overseas marketing campaign in Europe and the US to
promote Tepnel's Research Products and Services (RPS) based in Livingston,
Scotland.

This grant will enable Tepnel's pharmaceutical services business to market its
products and services to countries outside the UK.

Ben Matzilevich, CEO of Tepnel, said: "These grants will enable Tepnel to expand
its molecular diagnostics pipeline in high growth areas.   It will be used to
promote our growing pharmaceutical services and products in countries where we
do not have an established presence. Tepnel will continue to seek additional
grant funding for these and other projects and is optimistic it can reduce or
defer costs through grant funding and strategic partnerships."


                                     -Ends-



For further information:



Tepnel Life Sciences plc

Ben Matzilevich, CEO
Carol Smith
Tel: 0161 946 2200



Capital MS&L

Mary Clark or Catie Corcoran

Tel: +44 20 7307 5330


Seymour Pierce Limited
Mark Percy
Tel: +44 20 7107 8000



Notes to Editors:


About Tepnel Life Sciences plc

Tepnel Life Sciences (AIM:TED) is a UK-based international life sciences
products and services group with two divisions, Molecular Diagnostics and
Research Products & Services. The Company has laboratories, manufacturing and
operations in the USA, UK and France with 195 employees.

Tepnel provides test kits, reagents and services to two highly synergistic
markets, these being Molecular Diagnostics and Biomedical Research.

The company's strategy has been to identify high growth niche opportunities
within these multi-billion pound markets.  Tepnel focuses on these opportunities
with internally developed products, patents, expertise and know-how as well as
strategic acquisitions, to develop a leadership position within these defined
market segments.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

NRAOKNKKQBKDCFK

Ted Baker (LSE:TED)
Historical Stock Chart
From Jun 2024 to Jul 2024

Ted Baker (LSE:TED)
Historical Stock Chart
From Jul 2023 to Jul 2024